Multiple sclerosis Archives

Apitope Multiple Sclerosis ATX MS 1467 phase IIa 1

News and Trends 21 Feb 2017

A New Peptide Vaccine for Multiple Sclerosis Succeeds in Phase IIa

Apitope is developing therapeutic peptides to induce suppression of autoimmune responses towards self-antigens. Their recent phase IIa trial has revealed promising results for the treatment of multiple sclerosis. Multiple sclerosis (MS) is a hot topic these days. While a recent long-term study revealed the potential of hematopoietic stem cell transplantation for the treatment of MS, this treatment strategy is […]

February 21, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 30 Jan 2017

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small size and high solubility. The company has now received a milestone payment from Danish pharma Lundbeck for the development of the technology as a delivery […]

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Jan 2017

Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B

Actelion will be acquired by J&J for a whopping €27.9B, and its early R&D pipeline will be spun out into a new Switzerland-based outfit. The wait is over folks: Actelion, the largest biotech in Europe and one of the only 9 to make it to the billion-euro club in 2016, has just announced its acquisition by Johnson & Johnson for a […]

January 26, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 2 Jan 2017

An EU Project will tackle Multiple Sclerosis using Personalized Multi Omics

The MultipleMS Consortium has been granted €15M by the EU Horizon 2020 to improve the treatment of multiple sclerosis using personalized medicine. The EU Horizon 2020 has kicked off the year with a project to develop, validate, and exploit methods for the personalized treatment of multiple sclerosis (MS). The 21 institutions from 12 European countries and […]

January 2, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 24 Oct 2016

Here comes the First-ever Combination Therapy for Multiple Sclerosis

Actelion is overcoming the upcoming expiration of one of its most profitable patents and it’s using its strong position to make the leap into the crowded market of multiple sclerosis with the first-ever combination therapy. Actelion is one of the top billion-euro Biotechs in Europe and a leader in pulmonary arterial hypertension (PAH). Although the patent for […]

October 24, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Sep 2016

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

GeNeuro is developing a unique treatment for multiple sclerosis. We interviewed Miguel Payro, the company’s CFO, who explained its advantageous position against big pharma. GeNeuro raised €33M in its Euronext IPO in April and is currently competing against giants like Novartis and Biogen. Despite 2016’s dubious honor as “the worst year for IPO in 20 years”, this Switzerland-based company has managed to go […]

September 30, 2016 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 20 Sep 2016

UPDATE: Novartis is Favoured to Win the Race for a New MS Drug

Novartis is poised to kick off the next generation of multiple sclerosis treatments after siponimod performs well in Phase III. The company’s primary competitor had been Biogen, but its drug’s failure in Phase II leaves siponimod the last man standing. Novartis reports that its multiple sclerosis (MS) drug, siponimod, has reached its primary endpoint in Phase III […]

September 20, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 11 Feb 2016

Sanofi-Genzyme: Still successful 5 years after the acquisition?

Back in 2011, France’s biggest Pharmaceutical company Sanofi decided to purchase Genzyme Corp. for more than $20 billion, thus becoming the latest global drug giant to acquire a big biotech to foster its R&D pipeline. 5 years later, what’s the situation for Genzyme and Sanofi? So often when a large Pharma acquires a smaller Biotech, […]

February 11, 2016 - 3 minutesmins - By Dani Bancroft

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Multiple sclerosis

A New Peptide Vaccine for Multiple Sclerosis Succeeds in Phase IIa

‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier

Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B

An EU Project will tackle Multiple Sclerosis using Personalized Multi Omics

Here comes the First-ever Combination Therapy for Multiple Sclerosis

Interview: GeNeuro’s CFO explains its Unique Multiple Sclerosis Treatment

UPDATE: Novartis is Favoured to Win the Race for a New MS Drug

Sanofi-Genzyme: Still successful 5 years after the acquisition?

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!